A Family Study of Adults With Glioma
Status: | Completed |
---|---|
Conditions: | Brain Cancer, Brain Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - 100 |
Updated: | 4/6/2019 |
Start Date: | February 24, 1999 |
To advance understanding of environmental, behavioral and genetic causes of brain tumors in
adults, DCEG investigators initiated a multicenter case-control study of malignant and benign
tumors in adults in 1994. This four-year study was conducted at participating hospitals in
Boston, Phoenix, and Pittsburgh. Eligible cases were individuals greater than or equal to 18
years newly diagnosed with an intracranial glioma, meningioma or acoustic neuroma and treated
at one of the participating hospitals. The controls were patients admitted to neurological,
neurosurgical or general surgical services at the same three hospitals for any of a variety
of non-neoplastic conditions. By the end of the study, 811 brain tumor cases had been
accrued.
Information about a broad range of possible environmental, lifestyle, and genetic risk
factors was obtained from both cases and controls through a computer-assisted personal
interview (CAPI). The family history component obtained history and age at diagnosis of
cancer or benign brain tumors and selected other diseases, for all living and deceased first
degree relatives. A supplemental self-administered questionnaire covered diet, vitamin
supplements, alcohol consumption, and household use of electrical appliances. Blood samples
were obtained as a source of DNA. Currently, data analysis is in the early stages.
To increase our ability to examine both genetic and environmental components of brain tumor
risk, we decided to add a family studies component to the case-control study, focusing on
families of glioma cases. Initial contact with each family is made through the cases or, if a
case is deceased, through the next of kin. Cases or next of kin are asked to complete a
Family Health Questionnaire that updates the family medical history and provides contacting
information for all adult first degree relatives and more distant relatives with cancer.
Then, we contact all first degree relatives greater than or equal to age 18 years, and the
next of kin of deceased eligible relatives and invite them to complete a modified risk factor
interview conducted over the telephone. This interview obtains information about each
relative s personal and family history of cancer and other diseases, and history of risk
factor exposures, including all the major categories covered in the case-control study. Study
participants who complete the interview are then asked to provide buccal cells as a source of
DNA for future genotyping.
The glioma cases and their relatives will serve as a unique resource for both epidemiologic
and genetic analyses. Selected relatives can serve as controls for association thereby
eliminating concerns and population stratification. The study design also permits assessment
of specific genetic hypotheses that cannot be evaluated in a traditional case-control study.
Data from all first degree relatives of the glioma cases will be used in association studies
and segregation analysis. In addition, we can screen DNA from members of multiplex families
(families with 2 or more relatives with a primary CNS tumor) for mutations in candidate genes
known to be associated with glioma, and contribute data from selected multiplex families to
collaborative linkage studies to search for new genes conferring susceptibility to brain and
possibly related tumors.
adults, DCEG investigators initiated a multicenter case-control study of malignant and benign
tumors in adults in 1994. This four-year study was conducted at participating hospitals in
Boston, Phoenix, and Pittsburgh. Eligible cases were individuals greater than or equal to 18
years newly diagnosed with an intracranial glioma, meningioma or acoustic neuroma and treated
at one of the participating hospitals. The controls were patients admitted to neurological,
neurosurgical or general surgical services at the same three hospitals for any of a variety
of non-neoplastic conditions. By the end of the study, 811 brain tumor cases had been
accrued.
Information about a broad range of possible environmental, lifestyle, and genetic risk
factors was obtained from both cases and controls through a computer-assisted personal
interview (CAPI). The family history component obtained history and age at diagnosis of
cancer or benign brain tumors and selected other diseases, for all living and deceased first
degree relatives. A supplemental self-administered questionnaire covered diet, vitamin
supplements, alcohol consumption, and household use of electrical appliances. Blood samples
were obtained as a source of DNA. Currently, data analysis is in the early stages.
To increase our ability to examine both genetic and environmental components of brain tumor
risk, we decided to add a family studies component to the case-control study, focusing on
families of glioma cases. Initial contact with each family is made through the cases or, if a
case is deceased, through the next of kin. Cases or next of kin are asked to complete a
Family Health Questionnaire that updates the family medical history and provides contacting
information for all adult first degree relatives and more distant relatives with cancer.
Then, we contact all first degree relatives greater than or equal to age 18 years, and the
next of kin of deceased eligible relatives and invite them to complete a modified risk factor
interview conducted over the telephone. This interview obtains information about each
relative s personal and family history of cancer and other diseases, and history of risk
factor exposures, including all the major categories covered in the case-control study. Study
participants who complete the interview are then asked to provide buccal cells as a source of
DNA for future genotyping.
The glioma cases and their relatives will serve as a unique resource for both epidemiologic
and genetic analyses. Selected relatives can serve as controls for association thereby
eliminating concerns and population stratification. The study design also permits assessment
of specific genetic hypotheses that cannot be evaluated in a traditional case-control study.
Data from all first degree relatives of the glioma cases will be used in association studies
and segregation analysis. In addition, we can screen DNA from members of multiplex families
(families with 2 or more relatives with a primary CNS tumor) for mutations in candidate genes
known to be associated with glioma, and contribute data from selected multiplex families to
collaborative linkage studies to search for new genes conferring susceptibility to brain and
possibly related tumors.
To advance understanding of environmental, behavioral and genetic causes of brain tumors in
adults, DCEG investigators initiated a multicenter case-control study of malignant and benign
tumors in adults in 1994. This four-year study was conducted at participating hospitals in
Boston, Phoenix, and Pittsburgh. Eligible cases were individuals greater than or equal to 18
years newly diagnosed with an intracranial glioma, meningioma or acoustic neuroma and treated
at one of the participating hospitals. The controls were patients admitted to neurological,
neurosurgical or general surgical services at the same three hospitals for any of a variety
of non-neoplastic conditions. By the end of the study, 811 brain tumor cases had been
accrued.
Information about a broad range of possible environmental, lifestyle, and genetic risk
factors was obtained from both cases and controls through a computer-assisted personal
interview (CAPI). The family history component obtained history and age at diagnosis of
cancer or benign brain tumors and selected other diseases, for all living and deceased first
degree relatives. A supplemental self-administered questionnaire covered diet, vitamin
supplements, alcohol consumption, and household use of electrical appliances. Blood samples
were obtained as a source of DNA. Currently, data analysis is in the early stages.
To increase our ability to examine both genetic and environmental components of brain tumor
risk, we decided to add a family studies component to the case-control study, focusing on
families of glioma cases. Initial contact with each family is made through the cases or, if a
case is deceased, through the next of kin. Cases or next of kin are asked to complete a
Family Health Questionnaire that updates the family medical history and provides contacting
information for all adult first degree relatives and more distant relatives with cancer.
Then, we contact all first degree relatives greater than or equal to age 18 years, and the
next of kin of deceased eligible relatives and invite them to complete a modified risk factor
interview conducted over the telephone. This interview obtains information about each
relative s personal and family history of cancer and other diseases, and history of risk
factor exposures, including all the major categories covered in the case-control study. Study
participants who complete the interview are then asked to provide buccal cells as a source of
DNA for future genotyping.
The glioma cases and their relatives will serve as a unique resource for both epidemiologic
and genetic analyses. Selected relatives can serve as controls for association thereby
eliminating concerns and population stratification. The study design also permits assessment
of specific genetic hypotheses that cannot be evaluated in a traditional case-control study.
Data from all first degree relatives of the glioma cases will be used in association studies
and segregation analysis. In addition, we can screen DNA from members of multiplex families
(families with 2 or more relatives with a primary CNS tumor) for mutations in candidate genes
known to be associated with glioma, and contribute data from selected multiplex families to
collaborative linkage studies to search for new genes conferring susceptibility to brain and
possibly related tumors.
adults, DCEG investigators initiated a multicenter case-control study of malignant and benign
tumors in adults in 1994. This four-year study was conducted at participating hospitals in
Boston, Phoenix, and Pittsburgh. Eligible cases were individuals greater than or equal to 18
years newly diagnosed with an intracranial glioma, meningioma or acoustic neuroma and treated
at one of the participating hospitals. The controls were patients admitted to neurological,
neurosurgical or general surgical services at the same three hospitals for any of a variety
of non-neoplastic conditions. By the end of the study, 811 brain tumor cases had been
accrued.
Information about a broad range of possible environmental, lifestyle, and genetic risk
factors was obtained from both cases and controls through a computer-assisted personal
interview (CAPI). The family history component obtained history and age at diagnosis of
cancer or benign brain tumors and selected other diseases, for all living and deceased first
degree relatives. A supplemental self-administered questionnaire covered diet, vitamin
supplements, alcohol consumption, and household use of electrical appliances. Blood samples
were obtained as a source of DNA. Currently, data analysis is in the early stages.
To increase our ability to examine both genetic and environmental components of brain tumor
risk, we decided to add a family studies component to the case-control study, focusing on
families of glioma cases. Initial contact with each family is made through the cases or, if a
case is deceased, through the next of kin. Cases or next of kin are asked to complete a
Family Health Questionnaire that updates the family medical history and provides contacting
information for all adult first degree relatives and more distant relatives with cancer.
Then, we contact all first degree relatives greater than or equal to age 18 years, and the
next of kin of deceased eligible relatives and invite them to complete a modified risk factor
interview conducted over the telephone. This interview obtains information about each
relative s personal and family history of cancer and other diseases, and history of risk
factor exposures, including all the major categories covered in the case-control study. Study
participants who complete the interview are then asked to provide buccal cells as a source of
DNA for future genotyping.
The glioma cases and their relatives will serve as a unique resource for both epidemiologic
and genetic analyses. Selected relatives can serve as controls for association thereby
eliminating concerns and population stratification. The study design also permits assessment
of specific genetic hypotheses that cannot be evaluated in a traditional case-control study.
Data from all first degree relatives of the glioma cases will be used in association studies
and segregation analysis. In addition, we can screen DNA from members of multiplex families
(families with 2 or more relatives with a primary CNS tumor) for mutations in candidate genes
known to be associated with glioma, and contribute data from selected multiplex families to
collaborative linkage studies to search for new genes conferring susceptibility to brain and
possibly related tumors.
- INCLUSION CRITERIA:
Individuals who are eligible for this study include:
The 499 glioma cases who were interviewed for the case-control study between September,
1994 and July, 1998. The cases were enrolled through Joseph's Hospital and Medical Center
(including Barrow Neurological Institute), Phoenix, AZ; Brigham and Women's Hospital,
Boston, MA; and Western Pennsylvania Hospital, Pittsburgh, PA.
The following relatives greater than or equal to 18 years of age from simplex families: all
first degree relatives; the spouse(s) of a case, if the spouse(s) had children with the
case who are participating in the study.
The following relatives greater than or equal to 18 years of age from multiplex families:
all first and second degree relatives; more distant blood relatives with cancer (secondary
case); first degree relatives of every secondary case; the spouse(s) of every case or
secondary case if the spouse(s) had children with the case or secondary case who are
participating in the study; any blood relative not included above who connects a secondary
case to a case.
We found this trial at
3
sites
University of Arizona The University of Arizona is a premier, public research university. Established in...
Click here to add this to my saved trials
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials
Click here to add this to my saved trials